...
首页> 外文期刊>Journal of Cellular Physiology >State of the art in microRNA as diagnostic and therapeutic biomarkers in chronic lymphocytic leukemia
【24h】

State of the art in microRNA as diagnostic and therapeutic biomarkers in chronic lymphocytic leukemia

机译:艺术的microRNA诊断和状态治疗慢性淋巴细胞的生物标志物白血病

获取原文
获取原文并翻译 | 示例
           

摘要

Early diagnostic is one of the most important steps in cancer therapy which helps to design and choose a better therapeutic approach. The finding of biomarkers in various levels including genomics, transcriptomics, and proteomics levels could provide better treatment for various cancers such as chronic lymphocytic leukemia (CLL). The CLL is the one of main lymphoid malignancies which is specified by aggregation of mature B lymphocytes. Among different biomarkers (e.g., CD38, chromosomes abnormalities, ZAP‐70, TP53, and microRNA [miRNA]), miRNAs have appeared as new diagnostic and therapeutic biomarkers in patients with the CLL disease. Multiple lines of evidence indicated that deregulation of miRNAs could be associated with pathological events which are present in the CLL. These molecules have an effect on a variety of targets such as Bcl2, c‐fos, c‐Myc, TP53, TCL1, and STAT3 which play critical roles in the CLL pathogenesis. It has been shown that expression of miRNAs could lead to the activation of B cells and B cell antigen receptor (BCR). Moreover, exosomes containing miRNAs are one of the other molecules which could contribute to BCR stimulation and progression of CLL cells. Hence, miRNAs and exosomes released from CLL cells could be used as potential diagnostic and therapeutic biomarkers for CLL. This critical review focuses on a very important aspect of CLL based on biomarker discovery covers the pros and cons of using miRNAs as important diagnostics and therapeutics biomarkers for this deadly disease.
机译:早期诊断是最重要的一个在癌症治疗有助于设计和步骤选择一个更好的治疗方法。不同层次包括的生物标志物基因组、转录组和蛋白质组学水平可以提供更好的治疗各种慢性淋巴细胞白血病等癌症(CLL)。恶性肿瘤是指定的聚合成熟的B淋巴细胞。(例如,CD38,染色体异常,攻击高70TP53, microRNA [microRNA]), microRNA出现新的诊断和治疗性生物标志物慢性淋巴细胞白血病疾病患者。证据表明,microrna的放松管制可以与病理相关事件吗这是出现在慢性淋巴细胞白血病。影响等多种目标Bcl2 c高安全系数c高Myc TP53 TCL1, STAT3慢性淋巴细胞白血病发病机制中发挥着至关重要的作用。已被证明,microrna的表达可以吗导致B细胞和B细胞的激活抗原受体(BCR)。含有microrna的另一个分子这可能导致BCR刺激和慢性淋巴细胞白血病细胞的发展。液释放可以作为慢性淋巴细胞白血病细胞潜在的诊断和治疗性生物标志物慢性淋巴细胞白血病。慢性淋巴细胞白血病基于生物标志物的重要方面发现覆盖使用的利弊microrna是重要的诊断和治疗这个致命的疾病生物标志物。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号